mNemoscience: Turning Science Projects into Commercial Success
Sometimes an unconventional device company needs an unconventional investor. That's true of mNemoscience, which was launched from the MIT lab of Robert Langer to develop materials technology that combines the shape memory properties commonly associated with nitinol and biodegradability. The combined properties could represent important advances in a number of device areas, and the company is starting in coronary stents and sutures. But, not surprisingly, mNemoscience has taken a long time in its technology development efforts and has had to find just the right financing model. What mNemoscience had to offer its unconventional investor provides an instructive tale to medtech executives and scientists everywhere.
You may also be interested in...
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.
The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.
After concerns from the medtech industry that a 2017 final rule requires sponsors with knowledge of off-label use of their product to add it to their label, the US FDA is proposing to delete the confusing text.